Literature DB >> 26797368

Proton MR Spectroscopy for Monitoring Pathologic Changes in the Substantia Nigra and Globus Pallidus in Parkinson Disease.

Gang Wu1, Yi-Jian Shen2, Mei-Hua Huang1, Zhen Xing1, Ying Liu1, Jin Chen1.   

Abstract

OBJECTIVE: This retrospective study aimed to examine the relationship between the ratio of N-acetyl aspartate (NAA) to creatine in the substantia nigra (SN) and globus pallidus (GP) and the Hoehn-Yahr stage and Unified Parkinson Disease Rating Scale (UPDRS) score determined for patients with Parkinson disease (PD).
MATERIALS AND METHODS: Thirty patients with PD who underwent proton MR spectroscopy ((1)H-MRS) and for whom a Hoehn-Yahr stage and a UPDRS score for PD were determined were retrospectively reviewed. Hydrogen-1-MRS was used to measure the metabolite levels in the bilateral SN and GP.
RESULTS: The mean (± SD) age of the patients was 67.7 (± 10.6) years. The mean UPDRS score was 40.5 ± 13.9. Fourteen patients had PD of Hoehn-Yahr stages 1-2, and 16 patients had PD of Hoehn-Yahr stages 3-5. The NC ratio (the NAA-to-creatine ratio for the initially symptomatic side or the body divided by the NAA-to-creatine ratio for the contralateral side) for the bilateral GP (BGPNC) was significantly lower in the patients with stages 1-2 PD than in the patients with stages 3-5 PD (0.68 ± 0.23 vs 0.84 ± 0.11; p = 0.023). The NAA-to-creatine ratio for the initially symptomatic side of the SN was negatively correlated with the UPDRS score (r = -0.379; p = 0.039).
CONCLUSION: In early PD, the changes in the GP are more pronounced on the side affected at the onset of PD, which may contribute to the development of asymmetric symptoms and signs. Hydrogen-1-MRS shows promise as a modality for evaluating PD.

Entities:  

Keywords:  Hoehn-Yahr stage; Parkinson disease; globus pallidus; proton MR spectroscopy; substantia nigra

Mesh:

Substances:

Year:  2016        PMID: 26797368     DOI: 10.2214/AJR.14.14052

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  6 in total

1.  Proton Magnetic Resonance Spectroscopy for the Early Diagnosis of Parkinson Disease in the Substantia Nigra and Globus Pallidus: A Meta-Analysis With Trial Sequential Analysis.

Authors:  Wenbin Gu; Chen He; Juping Chen; Junchen Li
Journal:  Front Neurol       Date:  2022-06-16       Impact factor: 4.086

2.  Inhibitory motor dysfunction in parkinson's disease subtypes.

Authors:  Tao Gong; Yuanyuan Xiang; Muhammad G Saleh; Fei Gao; Weibo Chen; Richard A E Edden; Guangbin Wang
Journal:  J Magn Reson Imaging       Date:  2017-09-27       Impact factor: 4.813

3.  Detection and application of neurochemical profile by multiple regional 1H-MRS in Parkinson's disease.

Authors:  Jitian Guan; Yu Rong; Ye Wen; Huanze Wu; Hong Qin; Qingying Zhang; Wei Chen
Journal:  Brain Behav       Date:  2017-08-13       Impact factor: 2.708

4.  Effect of MAO-B Inhibitors on Neurometabolic Profile of Patients Affected by Parkinson Disease: A Proton Magnetic Resonance Spectroscopy Study.

Authors:  Lilla Bonanno; Rosella Ciurleo; Silvia Marino; Claudio Ruvolo; Rosa Morabito; Alessia Bramanti; Francesco Corallo
Journal:  J Clin Med       Date:  2022-03-30       Impact factor: 4.241

Review 5.  Current status of biomarker research in neurology.

Authors:  Jiri Polivka; Jiri Polivka; Kristyna Krakorova; Marek Peterka; Ondrej Topolcan
Journal:  EPMA J       Date:  2016-07-04       Impact factor: 6.543

6.  Does Side of Onset Influence the Pattern of Cerebral Atrophy in Parkinson's Disease?

Authors:  Maria C A Santos; Lidiane S Campos; Rachel P Guimarães; Camila C Piccinin; Paula C Azevedo; Luiza G Piovesana; Brunno Machado De Campos; Augusto C Scarparo Amato-Filho; Fernando Cendes; Anelyssa D'Abreu
Journal:  Front Neurol       Date:  2016-09-12       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.